Veracyte Secures Medicare Coverage for Prosigna Test
MolDX Medicare coverage for Veracyte’s Prosigna Breast Risk of Recurrence test takes effect Aug. 19, 2026, for eligible postmenopausal patients with ER-positive early-stage disease.
MolDX Medicare coverage for Veracyte’s Prosigna Breast Risk of Recurrence test takes effect Aug. 19, 2026, for eligible postmenopausal patients with ER-positive early-stage disease.